Dear Reader,

All of the research we’ve uncovered proves that Germany is going to be the next cannabis mecca and an absolute windfall for early-stage investors.

With a population of over 82 million, Germany is Europe’s number-one economy, and the German patient population for medical cannabis includes more than 79,000 active patients – up significantly from only around 800 in 2017.

Despite the massive profit potential in this untapped consumer base, hardly anybody’s talking about this incredible moneymaking opportunity.

Few businesses have access to the German cannabis market: it’s not a simple matter to acquire the licenses, capital, and connections necessary to make inroads into this region.

It’s one of the reasons why we’ve made ICC International Cannabis Corp. (CSE: WRLD.U & US: WLDCF) a top stock suggestion for our letter. 

I believe this is one of the best international cannabis deals anyone can invest in right now, with:

  • Distribution or supply agreements with over 39,000 corporate and independent pharmacies
  • Europe’s first dedicated insurance program for medical cannabis patients
  • 16 licenses spanning 12 countries and four continents
  • 30,000-kilogram EU-GMP medical cannabis import agreement over a three-year term with Wayland
  • Library of 430 proprietary genetics, seeds, and strains
  • Forecasted production of 15,000 kg of CBD isolate in 2019
  • Over 275 metric tonnes of extraction-ready hemp inventories, resulting in near-immediate access to superior CBD concentrates
  • Closing on CAD$45 million this past week
  • In Germany, their cultivation facility is so large that the next in size from a competitor is just 1.7% the size!
  • Exposure to the E.U. market, Africa, South America, and they’re working to enter Australia

***For one moment, I want you to just think about being the manager of a large institution or family wealth office that is looking for some international cannabis exposure*** I say this because part of the reason why I am screaming from the roof tops about the cannabis space is because when the institutional money comes in, I believe this sector will go vertical and there will be trillions of dollars looking for quality investments.

International Cannabis holds a highly-coveted German medical cannabis import license and is preparing to move vast quantities of legal cannabis product into the country:

This is all possible because ICC made a brilliant move, inking a deal to acquire nearly half of Wayland Group’s international assets and license portfolio, which will provide unprecedented access to the German cannabis market.

93% Of Investors Generate Annual Returns, Which Barely Beat Inflation.

Wealth Education and Investment Principles Are Hidden From Public Database On Purpose!

Build The Knowledge Base To Set Yourself Up For A Wealthy Retirement and Leverage The Relationships We Are Forming With Proven Small-Cap Management Teams To Hit Grand-Slams!

    ICC now holds a three-year supply contract to import 35,000 kilograms of medical-grade cannabis, so you can only imagine the revenues this will generate over the coming months and years.

    This historic joint venture will grant ICC a nearly 50% interest in a German medical cannabis import license, along with a massive 840,000-square-foot facility with a 50,000-square-foot certified packaging/distribution center.

    In addition to all of that, the Wayland deal will grant ICC an annual production of over 2,400 kilograms of CBD isolate, 165 hectares of CBD cultivation operations, and a three-year agreement to supply medical cannabis to 2,200 pharmacies.

    The size of ICC’s Ebersbach facility in Germany has to be seen to be believed – it dwarfs their competitors’ cultivation facilities. And within Germany, there’s no competition whatsoever, as the cultivation facility closest to their size in the country is literally 1.7% the size of the Ebersbach facility:

    To give you a visual idea of how massive the Ebersbach facility really is, let’s just say that it’s somewhere between the Sydney Opera House and the gigantic O2 Arena in size:

    ***ICC’s operations aren’t only in Germany, as the Wayland Group deal will also provide them with large-scale acquisitions in Switzerland, Italy, Argentina, the U.K., Colombia, Malta, and Australia. 

    ***ICC also has significant cannabis holdings outside of the Wayland acquisitions in Denmark, Poland, Greece, Italy, Portugal, Argentina, and Africa, among other locations.

    With Germany on track to become the next rainmaker in the global cannabis scene, the Wayland deal is putting International Cannabis Corp. far ahead of their competitors.

    For exposure to the highly-promising and legal German cannabis market, as well as a strong foothold in multiple regions across the E.U., South America, and Africa, consider buying shares of ICC International Cannabis (CSE: WRLD.U & US: WLDCF).

    For me personally, ICC International Cannabis shares are an absolute must-have in my family’s portfolio.

    Best Regards,

    Daniel Ameduri

    93% Of Investors Generate Annual Returns, Which Barely Beat Inflation.

    Wealth Education and Investment Principles Are Hidden From Public Database On Purpose!

    Build The Knowledge Base To Set Yourself Up For A Wealthy Retirement and Leverage The Relationships We Are Forming With Proven Small-Cap Management Teams To Hit Grand-Slams!

      Legal Notice: This work is based on SEC filings, current events, interviews, corporate press releases and what we’ve learned as financial journalists. It may contain errors and you shouldn’t make any investment decision based solely on what you read here. It’s your money and your responsibility. The information herein is not intended to be personal legal or investment advice and may not be appropriate or applicable for all readers. If personal advice is needed, the services of a qualified legal, investment or tax professional should be sought.

      Never base any decision off of our emails. stock profiles are intended to be stock ideas, NOT advice. The ideas we present are high risk and you can lose your entire investment, we are not stock pickers, market timers, investment advisers, and you should not base any investment decision off our website, emails, videos, or anything we publish.  Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this profile was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. Never base any investment decision from information contained in our website or emails or any or our publications. Our report is not intended to be, nor should it be construed as an offer to buy or sell, or a solicitation of an offer to buy or sell securities, or as a recommendation to purchase anything. This publication may provide the addresses or contain hyperlinks to websites; we disclaim any responsibility for the content of any such other websites.  Please use our site as a place to get ideas. Enjoy our videos and news analysis, but never make an investment decision off of anything we say. Please review our entire disclaimer at